Citation: | Wang Huimin, Liao Meilin, Chen Yurong, et al. The Response Rate of High Dose Epirubicin in Comparison with Conventional Dose on NSCLC[J]. Cancer Research on Prevention and Treatment, 1999, 26(2): 133-135. |
[1] |
Weiss RB.The anthracyclines:Wil we ever find a better do xorubicin ? Semis Onceh 1992, 19(6):670
|
[2] |
Rosen HR,Minow RA,Leier CV,et al.Epirubicin and Doxorrubicin:A comparison of the characteristic therapeutic activity and toxicity.Cancer Treat Rev,1993,19(3):197
|
[3] |
林震琼,徐昌文,等.小细胞肺癌化疗后的病理学观察--附48例分析.中华肿瘤杂志,1988, 6(10):452-454
|
[4] |
Martoni A,Melotti B, et al. High-dose epirubicin for untreated patients with advanced tumours a phase I study.Eur-J-Cancer,1990, 26(11-12):1137-1140
|
[5] |
Cersoimo RJ,et al.Epirubicin:a review of the pliarmacology,clinical activity,and adverse effects of anadriamvcin anabgue.,J-Clim-On-col, 1986,4:425-439
|
[6] |
Martoni A, et al.Activiy of high dose epimbicin in advanced non-small-cell lung Cancer. Eur-J-Cancer,1991, 27(10):1231-1234
|
[7] |
Martoiu A. Guaraldi M, et al.A phrase II study of high- dose epirubici plus cisplatinum in advanced non-small-cell lung cancer (NSCLC),Ann-oncol 1992, 12,3(10):864-866
|